Sotatercept for treating pulmonary arterial hypertension [ID6163]: NICE Single Technology Appraisal

Clare Robertson; Dwayne Boyers; Thenmalar Vadiveloo; David Cooper; Melanie  Brewis; Colin McCabe; Paul Manson; Miriam Brazzelli; Graham Scotland

Sotatercept for treating pulmonary arterial hypertension [ID6163]: NICE Single Technology Appraisal

Clare Robertson
, Dwayne Boyers
, Thenmalar Vadiveloo
, David Cooper
, Melanie Brewis
, Colin McCabe
, Paul Manson
, Miriam Brazzelli
, Graham Scotland^* (Corresponding Author)

^*Corresponding author for this work

Research output: Book/Report › Commissioned Report

Abstract

Suggested remit: To appraise the clinical and cost effectiveness of sotatercept within its marketing authorisation for treating pulmonary arterial hypertension.

Status: In progress

Original language	English
Publisher	Aberdeen HTA Group
Commissioning body	National Institute for Health and Care Excellence (NICE)
Publication status	Accepted/In press - 21 May 2025

Bibliographical note

Contribution of authors
CR reviewed and critiqued the clinical effectiveness evidence presented in the company submission and drafted the background section; TV and DC checked and critiqued the statistical analyses presented in the company submission; Miriam Brazzelli oversaw and commented on the critique of clinical effectiveness; DB and GS reviewed and critiqued the cost-effectiveness evidence and economic model presented in the company submission; Melannie Brewis and CB provided expert clinical guidance and comments on the draft report; PM checked and critiqued the company’s search strategies. GS coordinated all aspects of this appraisal and is the guarantor of this report. All authors contributed to the writing of this report and approved its final version.

Funding

Source of funding: This report was commissioned by the NIHR Evidence Synthesis Programme as project number NIHR166802.

Access to Document

https://www.nice.org.uk/guidance/gid-ta11103/documents/committee-papersLicence: Other

Cite this

@book{7efb1542ee4e42b5a389cc8455f9d9cf,

title = "Sotatercept for treating pulmonary arterial hypertension [ID6163]: NICE Single Technology Appraisal",

abstract = "Suggested remit: To appraise the clinical and cost effectiveness of sotatercept within its marketing authorisation for treating pulmonary arterial hypertension. Status: In progress",

author = "Clare Robertson and Dwayne Boyers and Thenmalar Vadiveloo and David Cooper and Melanie Brewis and Colin McCabe and Paul Manson and Miriam Brazzelli and Graham Scotland",

note = "Contribution of authors CR reviewed and critiqued the clinical effectiveness evidence presented in the company submission and drafted the background section; TV and DC checked and critiqued the statistical analyses presented in the company submission; Miriam Brazzelli oversaw and commented on the critique of clinical effectiveness; DB and GS reviewed and critiqued the cost-effectiveness evidence and economic model presented in the company submission; Melannie Brewis and CB provided expert clinical guidance and comments on the draft report; PM checked and critiqued the company{\textquoteright}s search strategies. GS coordinated all aspects of this appraisal and is the guarantor of this report. All authors contributed to the writing of this report and approved its final version.",

year = "2025",

month = may,

day = "21",

language = "English",

publisher = "Aberdeen HTA Group",

}

TY - BOOK

T1 - Sotatercept for treating pulmonary arterial hypertension [ID6163]

T2 - NICE Single Technology Appraisal

AU - Robertson, Clare

AU - Boyers, Dwayne

AU - Vadiveloo, Thenmalar

AU - Cooper, David

AU - Brewis, Melanie

AU - McCabe, Colin

AU - Manson, Paul

AU - Brazzelli, Miriam

AU - Scotland, Graham

N1 - Contribution of authors CR reviewed and critiqued the clinical effectiveness evidence presented in the company submission and drafted the background section; TV and DC checked and critiqued the statistical analyses presented in the company submission; Miriam Brazzelli oversaw and commented on the critique of clinical effectiveness; DB and GS reviewed and critiqued the cost-effectiveness evidence and economic model presented in the company submission; Melannie Brewis and CB provided expert clinical guidance and comments on the draft report; PM checked and critiqued the company’s search strategies. GS coordinated all aspects of this appraisal and is the guarantor of this report. All authors contributed to the writing of this report and approved its final version.

PY - 2025/5/21

Y1 - 2025/5/21

N2 - Suggested remit: To appraise the clinical and cost effectiveness of sotatercept within its marketing authorisation for treating pulmonary arterial hypertension. Status: In progress

AB - Suggested remit: To appraise the clinical and cost effectiveness of sotatercept within its marketing authorisation for treating pulmonary arterial hypertension. Status: In progress

UR - https://www.nice.org.uk/guidance/indevelopment/gid-ta11103

M3 - Commissioned Report

BT - Sotatercept for treating pulmonary arterial hypertension [ID6163]

PB - Aberdeen HTA Group

ER -

Sotatercept for treating pulmonary arterial hypertension [ID6163]: NICE Single Technology Appraisal

Abstract

Bibliographical note

Funding

Access to Document

Other files and links

Fingerprint

Cite this